Inventor · disambiguated record
John Flanagan
Also filed as: FLANAGAN JOHN · FLANAGAN JOHN G · FLANAGAN JOHN GERARD
26 granted patents·11 pending applications·460 citations·filing 1993–2024
96Inventor score
Files withAMICUS THERAPEUTICS INC11HARVARD COLLEGE7ARVINAS OPERATIONS INC3AMICUS THERAPEUTICS2FLANAGAN JOHN G2
Top patents by PatentIndex Score
37 records- 0198USRE48608EMethod to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2018·Granted Jun 29, 2021·36 cites·44 claims
- 0298US10813921B2Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2018·Granted Oct 27, 2020·39 cites·18 claims
- 0398US9545397B2Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2015·Granted Jan 17, 2017·50 cites·1 claims
- 0496US8592362B2Method to predict response to pharmacological chaperone treatment of diseasesBENJAMIN ELFRIDA·Filed 2010·Granted Nov 26, 2013·112 cites·4 claims
- 0594US9095584B2Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS·Filed 2013·Granted Aug 4, 2015·52 cites·10 claims
- 0692US9404100B2High concentration alpha-glucosidase compositions for the treatment of Pompe diseaseAMICUS THERAPEUTICS INC·Filed 2013·Granted Aug 2, 2016·16 cites·20 claims
- 0792US9303249B2High concentration α-glucosidase compositions for the treatment of Pompe diseaseAMICUS THERAPEUTICS INC·Filed 2013·Granted Apr 5, 2016·15 cites·18 claims
- 0887US10512677B2High concentration alpha-glucosidase compositions for the treatment of pompe diseaseAMICUS THERAPEUTICS INC·Filed 2018·Granted Dec 24, 2019·4 cites·15 claims
- 0987US10046033B2High concentration alpha-glucosidase compositions for the treatment of Pompe diseaseAMICUS THERAPEUTICS INC·Filed 2016·Granted Aug 14, 2018·4 cites·20 claims
- 1081US12419937B2High concentration alpha-glucosidase compositions for the treatment of Pompe diseaseAMICUS THERAPEUTICS INC·Filed 2022·Granted Sep 23, 2025·0 cites·18 claims
- 1178US5795734AEPH receptor ligands, and uses related theretoHARVARD COLLEGE·Filed 1995·Granted Aug 18, 1998·59 cites·26 claims
- 1277US9744188B2Methods of promoting neuronal outgrowth by gypican 2 that binds to receptor protein tyrosine phosphatase sigmaFLANAGAN JOHN G·Filed 2012·Granted Aug 29, 2017·8 cites·9 claims
- 1376US2025082621A9Method To Predict Response To Pharmacological Chaperone Treatment Of DiseasesAMICUS THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1475US7381708B2Suppression of eIF5A1 expression by the use of antisense oligonucleotides for the prevention of retinal cell death in the glaucomatous eyeSENSCO TECHNOLOGIES INC·Filed 2003·Granted Jun 3, 2008·8 cites·7 claims
- 1574US8242256B2siRNA useful to supress expression of EIF-5A1THOMPSON JOHN E·Filed 2009·Granted Aug 14, 2012·2 cites·11 claims
- 1674US5789182ASystem for assaying binding to a heparin-binding growth factor receptorCHILDRENS MEDICAL CENTER·Filed 1993·Granted Aug 4, 1998·33 cites·28 claims
- 1772US11808772B2Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis statusBIO RAD EUROPE GMBH·Filed 2018·Granted Nov 7, 2023·2 cites·1 claims
- 1871US11278599B2High concentration alpha-glucosidase compositions for the treatment of Pompe diseaseAMICUS THERAPEUTICS INC·Filed 2019·Granted Mar 22, 2022·0 cites·20 claims
- 1968US2025120968A1Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2024·Application pending·0 cites
- 2059US2017003301A1Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS·Filed 2016·Application pending·0 cites
- 2158US12208095B2Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degradersARVINAS OPERATIONS INC·Filed 2020·Granted Jan 28, 2025·0 cites·31 claims
- 2256US2011152319A1Method to predict response to pharmacological chaperone treatment of diseasesAMICUS THERAPEUTICS INC·Filed 2010·Application pending·0 cites
- 2356US2022400943A1Machine learning methods for creating structure-derived visual field priorsZEISS CARL MEDITEC INC·Filed 2020·Application pending·0 cites
- 2454US7662796B2Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1SENESCO TECHNOLOGIES INC·Filed 2005·Granted Feb 16, 2010·0 cites·11 claims
- 2552US2024354924A1Few-shot learning for processing microscopy imagesFEI CO·Filed 2023·Application pending·0 cites
- 2652US2022193072A1Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraderARVINAS OPERATIONS INC·Filed 2021·Application pending·0 cites
- 2751US2002156239A1EPH receptor ligands, and uses related theretoFiled 2001·Application pending·0 cites
- 2847US2016266124A1Pre-haptoglobin-2 monoclonal antibodies and uses thereofBIO RAD LABORATORIES INC·Filed 2014·Application pending·0 cites
- 2941US6919313B2Protein waving a PDZ and a RGS domainHARVARD COLLEGE·Filed 2002·Granted Jul 19, 2005·0 cites·3 claims
- 3040US6399326B1Nucleic acids encoding neural/pancreatic receptor tyrosine phosphataseHARVARD COLLEGE·Filed 1997·Granted Jun 4, 2002·9 cites·15 claims
- 3139US2012083010A1Method for diagnosing pompe diseaseDO HUNG V·Filed 2011·Application pending·0 cites
- 3238US11439615B2Lipoxin and lipoxin analogue mediated neuroprotection and treatmentsUNIV HEALTH NETWORK·Filed 2018·Granted Sep 13, 2022·0 cites·17 claims
- 3338US5554499ADetection and isolation of ligandsHARVARD COLLEGE·Filed 1994·Granted Sep 10, 1996·5 cites·46 claims
- 3437US5801000ADetection and isolation of receptorsHARVARD COLLEGE·Filed 1996·Granted Sep 1, 1998·4 cites·5 claims
- 3537US2012231014A1Neural RegenerationFLANAGAN JOHN G·Filed 2010·Application pending·0 cites
- 3635US6268476B1EPH receptor ligands, and uses related theretoHARVARD COLLEGE·Filed 1994·Granted Jul 31, 2001·2 cites·11 claims
- 3727US6777536B1EPH receptor ligands, and uses related theretoHARVARD COLLEGE·Filed 1995·Granted Aug 17, 2004·0 cites·14 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →